BIOMARIN PHARMACEUTICAL Business Summary

BioMarin Pharmaceutical Inc. (BMRN) is a global biotechnology leader specializing in the development and commercialization of high-premium therapies for rare and ultra-orphan genetic diseases. The company’s revenue model is primarily driven by product sales across four key therapeutic segments: skeletal conditions (led by the growth-driver Voxzogo for achondroplasia), phenylketonuria (Palynziq and Kuvan), mucopolysaccharidosis (Vimizim and Naglazyme), and hemophilia A (Roctavian). In a transformative move in late 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.7 billion, significantly diversifying its portfolio with the addition of Galafold for Fabry disease and the Pombiliti/Opfolda duo for Pompe disease. BioMarin competes directly with rare disease specialists such as Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical, Sarepta Therapeutics, and Ascendis Pharma; it maintains a dominant market position by leveraging complex manufacturing processes and deep regulatory moats to address high-unmet medical needs in niche patient populations. Founded in 1997 by Christopher M. Starr, Ph.D., and Grant W. Denison, BioMarin is currently led by President and CEO Alexander Hardy, who joined in late 2023 following a distinguished tenure as CEO of Genentech. The executive leadership team includes Brian R. Mueller as Executive Vice President and CFO, James Sabry as EVP and Chief Business Officer, and Cristin Hubbard as EVP and Chief Commercial Officer. The company’s strategic direction is overseen by a board chaired by Richard A. Meier, with recent high-profile additions such as former Horizon Therapeutics CEO Timothy P. Walbert. BioMarin’s capital structure is characterized by high institutional density, with major stakeholders including Vanguard, BlackRock, and State Street, reflecting strong investor confidence in its pivot toward a 40% non-GAAP operating margin target by 2026.